Impact of PKM linkers on biodistribution characteristics of the 99mTc-labeled cyclic RGDfK dimer

Bioconjugate Chemistry

Volumn 17, Issue 6, 2006, Pages 1499-1507

  Liu, Shuang ^a   He, Zhengjie ^a   Hsieh, Wen Yuan ^a   Kim, Young Seung ^a   Jiang, Young ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATION; LIGANDS; SYNTHESIS (CHEMICAL); TUMORS;

ATHYMIC; BINDING CAPABILITY; BIODISTRIBUTIONS; BREAST CANCER XENOGRAFTS; HUMAN BREAST CANCER; IN-VIVO; INTEGRINS; LIGAND COMPLEXES; NUDE MICE; VIVO EVALUATION;

COMPLEXATION;

15 AMINO 4,7,10,13 TETRAOXAPENTADECANOIC ACID; 6 HYDRAZINONICOTINAMIDE; ALKANOIC ACID; ARGINYLGLYCYLASPARTIC ACID; CYCLOPEPTIDE; DIMER; GLUTAMIC ACID; GLUTAMYL[CYCLO(LYSYLARGINYLGLYCYLASPARTYL DEXTRO PHENYLALANYL)]CYCLO(LYSYLARGINYLGLYCYLASPARTYL DEXTRO PHENYLALANINE); HYDRAZINE DERIVATIVE; LIGAND; LYSINE; NICOTINAMIDE DERIVATIVE; SU 016; TECHNETIUM 99M; TRACER; TRICINE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; BREAST CANCER; CANCER GRAFT; COMPLEX FORMATION; CONTROLLED STUDY; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG SYNTHESIS; HUMAN; HUMAN CELL; ISOTOPE LABELING; KIDNEY; LIVER; LUNG; MOUSE; NONHUMAN; NUDE MOUSE; PEPTIDE SYNTHESIS; TISSUE DISTRIBUTION;

MUS MUSCULUS;

EID: 33845218877     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc060235l     Document Type: Article

References (39)

1. 99mTc-Labeling of a hydrazinonicotinamide- conjugated vitronectin receptor antagonist useful for imaging tumors. Bioconjugate Chem. 12, 624-629.
2. 99mTc complexes of a HYNIC-conjugated cyclic RGDfK dimer. Bioconjugate Chem. 16, 1580-1588.
3. 3 expression. Bioconjugate Chem. 17, 1069-1076.
4. 3-positive breast cancer. J. Nucl. Med. Submitted.
5. 64Cu-labeled dimeric RGD peptides. Mol. Imaging Biol. 6, 350-359.
6. 18F-labeled dimeric RGD peptide. Mol. Imaging 3, 96-104.
7. 64Cu-labeled tetrameric RGD peptide. J. Nucl. Med. 46, 1707-1718.
8. 3 integrin binding peptides in a nude mouse model. Cancer Res. 62, 6146-6151.
9. Janssen, M., Oyen, W. J. G., Massuger, L. F. A. G., Frielink, C., Dijkgraaf, I., Edwards, D. S., Rajopadyhe, M., Corsten, F. H. M., and Boerman, O. C. (2002) Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother. Radiopharm. 17, 641-646.
10. Poethko, T., Schottelius, M., Thumshirn, G., Herz, M., Haubner, R., Henriksen, G., Kessler, H., Schwaiger, M., and Wester, H.-J. (2004) Chemoselective pre-conjugate radiohalogenation of unprotected mono- and multimeric peptides via oxime formation. Radiochim. Acta 92, 317-327.
11. Thumshirn, G., Hersel, U., Goodman, S. L., and Kessler, H. (2003) Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation. Chem. - Eur. J. 9, 2717-2725.
12. Liu, S., and Edwards, D. S. (2002) Fundamentals of receptor-based diagnostic metalloradiopharmaceuticals. Top. Curr. Chem. 222, 259-278.
13. Liu, S. (2004) The role of coordination chemistry in development of target-specific radiopharmaceuticals. Chem. Soc. Rev. 33, 1-18.
14. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals. Chem. Rev. 99, 2235-2268.
15. Haubner, R., Wester, H. J., Senekowitsch-Schmidtke, R., Diefenbach, B.. Kessler, H., Stöcklin, G., and Schwaiger, M. (1999) RGD-peptides for tumor targeting: biological evaluation of radioiodinated analogs and introduction of a novel glycosylated peptide with improved biokinetics. J. Labelled Compd. Radiopharm. 40, 383-385.
16. 3 integrin antagonists: a new class of tracers for tumor imaging. J. Nucl. Med. 40, 1061-1071.
17. Haubner, R., Wester, H. J., Burkhart, F., Senekowtisch-Schmidtke, R., Weber, W., Goodman, S. L., Kessler, H., and Schwaiger, M. (2001) Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J. Nucl. Med. 42, 326-336.
18. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 61, 1781-1785.
19. 18F-Galacto-RGD in cancer patients. J. Nucl. Med. 46, 1333-1341.
20. 18F]Galacto-RGD. PLOS Med. 2 e70, 244-252.
21. 3 antagonists for tumor imaging and radiotherapy. Cancer Biother. Radiopharm. 18, 627-641.
22. 3 receptor antagonist: Different but biologically equivalent. Bioconjugate Chem. 15, 235-241.
23. Haubner, R., and Wester, H. R. (2004) Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr. Pharm. Des. 10, 1439-1455.
24. Poethko, T., Thumshirn, G., Hersel, U., Rau, F., Haubner, R., Schwaiger, M., Kessler, H., and Wester, H. J. (2003) Improved tumor uptake, tumor retention and tumor/background ratios of pegylated RGD multimers. J. Nucl. Med. 44, 46P.
25. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl. Med. Biol. 31, 179-189.
26. 125I-labeled RGD peptide are improved by PEGylation. Nucl. Med. Biol. 31, 11-19.
27. 3-targeted imaging of lung cancer. Neoplasia 7, 271-279.
28. 3 expression. Mini-Rev. Med. Chem. 6, 227-234.
29. 3 directed radiopharmaceuticals for tumor imaging. Drugs Future 28, 551-564.
30. 3-targeted radiotracers for tumor imaging. Mol. Pharm. 3, 472-487.
31. Liu, S., and Edwards, D. S. (2001) Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. Bioconjugate Chem. 12, 7-34.
32. 99mTc-labeled radiopharmaceuticals. Bioconjugate Chem. 10, 808-814.
33. 2 formulation for RP444: a new radiopharmaceutical for thrombus imaging. J. Pharm. Sci. 90, 114-123.
34. 4 receptor antagonist useful for imaging infection and inflammation. Bioconjugate Chem. 13, 881-886.
35. 99mTc-labeling of small biomolecules. Top. Curr. Chem. 252, 117-153.
36. 99mTc. Bioconjugate Chem. 8, 146-154.
37. 99mTc-labeling of hydrazinonicotinamide-modified biologically active molecules using imine-N containing heterocycles as coligands. Bioconjugate Chem. 9, 583-595.
38. Liu, S., Edwards, D. S., Harris, A. R., Heminway, S. J., and Barrett, J. A. (1999) Technetium complexes of a hydrazinonicotinamide-conjugated cyclic peptide and 2-hydrazinopyridine: Synthesis and characterization. Inorg. Chem. 38, 1326-1335.
39. 3 expression. Nuklearmedizin 43, 26-32.